A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study

W. Kenneth Washburn, Lewis W. Teperman, Thomas G. Heffron, David D. Douglas, Steven Gay, Eliezer Katz, Goran B G Klintmalm

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This study evaluated the pharmacokinetics and pharmacodynamics of a novel 3-dose regimen of daclizumab in de novo hepatitis C liver transplant recipients. In 30 of 156 recipients receiving daclizumab, mycophenolate mofetil, tacrolimus, and no steroids (Arm 3 of Hep C 3 Liver Study), daclizumab (2, 2, and 1 mg/kg, respectively) was given on days 1, 3, and 8 posttransplant, respectively, with trough, peak (Cmax), and CD25 saturation (CDsat) measured sequentially. Mean daclizumab Cmax was 50.3 Ag/mL on day 1, and mean trough levels were 21.8, 25.7, and 9.9 μg/mL on days 3, 8, and 30, respectively. A significant decline in CDsat (mean, 15.7% to 4.7%) was observed on day 1 and was sustained throughout the study (2.8% on day 30). Daclizumab concentration ≥5 μg/mL was the level where most of the effect on CDsat was noticed. Elevated baseline CDsat, was observed in African Americans, patients weighing ≤75 kg, and patients <60 years of age. After 365 days, 2 patients had experienced 3 rejections, 10 patients had recurrent hepatitis C, 4 patients died, and 2 grafts were lost. In conclusion, this novel 3-dose regimen is effective in rapidly achieving high therapeutic concentration of daclizumab and a significant decline in CDsat lasting over 30 days.

Original languageEnglish (US)
Pages (from-to)585-591
Number of pages7
JournalLiver Transplantation
Volume12
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Hepatitis C
Pharmacokinetics
Liver
Mycophenolic Acid
Tacrolimus
African Americans
daclizumab
Transplant Recipients
Arm
Steroids
Transplants

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Washburn, W. K., Teperman, L. W., Heffron, T. G., Douglas, D. D., Gay, S., Katz, E., & Klintmalm, G. B. G. (2006). A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study. Liver Transplantation, 12(4), 585-591. https://doi.org/10.1002/lt.20631

A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C : A pharmacokinetic and pharmacodynamic study. / Washburn, W. Kenneth; Teperman, Lewis W.; Heffron, Thomas G.; Douglas, David D.; Gay, Steven; Katz, Eliezer; Klintmalm, Goran B G.

In: Liver Transplantation, Vol. 12, No. 4, 04.2006, p. 585-591.

Research output: Contribution to journalArticle

Washburn, WK, Teperman, LW, Heffron, TG, Douglas, DD, Gay, S, Katz, E & Klintmalm, GBG 2006, 'A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study', Liver Transplantation, vol. 12, no. 4, pp. 585-591. https://doi.org/10.1002/lt.20631
Washburn, W. Kenneth ; Teperman, Lewis W. ; Heffron, Thomas G. ; Douglas, David D. ; Gay, Steven ; Katz, Eliezer ; Klintmalm, Goran B G. / A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C : A pharmacokinetic and pharmacodynamic study. In: Liver Transplantation. 2006 ; Vol. 12, No. 4. pp. 585-591.
@article{32188f687b5c4202b927fa0d39a5f27a,
title = "A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study",
abstract = "This study evaluated the pharmacokinetics and pharmacodynamics of a novel 3-dose regimen of daclizumab in de novo hepatitis C liver transplant recipients. In 30 of 156 recipients receiving daclizumab, mycophenolate mofetil, tacrolimus, and no steroids (Arm 3 of Hep C 3 Liver Study), daclizumab (2, 2, and 1 mg/kg, respectively) was given on days 1, 3, and 8 posttransplant, respectively, with trough, peak (Cmax), and CD25 saturation (CDsat) measured sequentially. Mean daclizumab Cmax was 50.3 Ag/mL on day 1, and mean trough levels were 21.8, 25.7, and 9.9 μg/mL on days 3, 8, and 30, respectively. A significant decline in CDsat (mean, 15.7{\%} to 4.7{\%}) was observed on day 1 and was sustained throughout the study (2.8{\%} on day 30). Daclizumab concentration ≥5 μg/mL was the level where most of the effect on CDsat was noticed. Elevated baseline CDsat, was observed in African Americans, patients weighing ≤75 kg, and patients <60 years of age. After 365 days, 2 patients had experienced 3 rejections, 10 patients had recurrent hepatitis C, 4 patients died, and 2 grafts were lost. In conclusion, this novel 3-dose regimen is effective in rapidly achieving high therapeutic concentration of daclizumab and a significant decline in CDsat lasting over 30 days.",
author = "Washburn, {W. Kenneth} and Teperman, {Lewis W.} and Heffron, {Thomas G.} and Douglas, {David D.} and Steven Gay and Eliezer Katz and Klintmalm, {Goran B G}",
year = "2006",
month = "4",
doi = "10.1002/lt.20631",
language = "English (US)",
volume = "12",
pages = "585--591",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C

T2 - A pharmacokinetic and pharmacodynamic study

AU - Washburn, W. Kenneth

AU - Teperman, Lewis W.

AU - Heffron, Thomas G.

AU - Douglas, David D.

AU - Gay, Steven

AU - Katz, Eliezer

AU - Klintmalm, Goran B G

PY - 2006/4

Y1 - 2006/4

N2 - This study evaluated the pharmacokinetics and pharmacodynamics of a novel 3-dose regimen of daclizumab in de novo hepatitis C liver transplant recipients. In 30 of 156 recipients receiving daclizumab, mycophenolate mofetil, tacrolimus, and no steroids (Arm 3 of Hep C 3 Liver Study), daclizumab (2, 2, and 1 mg/kg, respectively) was given on days 1, 3, and 8 posttransplant, respectively, with trough, peak (Cmax), and CD25 saturation (CDsat) measured sequentially. Mean daclizumab Cmax was 50.3 Ag/mL on day 1, and mean trough levels were 21.8, 25.7, and 9.9 μg/mL on days 3, 8, and 30, respectively. A significant decline in CDsat (mean, 15.7% to 4.7%) was observed on day 1 and was sustained throughout the study (2.8% on day 30). Daclizumab concentration ≥5 μg/mL was the level where most of the effect on CDsat was noticed. Elevated baseline CDsat, was observed in African Americans, patients weighing ≤75 kg, and patients <60 years of age. After 365 days, 2 patients had experienced 3 rejections, 10 patients had recurrent hepatitis C, 4 patients died, and 2 grafts were lost. In conclusion, this novel 3-dose regimen is effective in rapidly achieving high therapeutic concentration of daclizumab and a significant decline in CDsat lasting over 30 days.

AB - This study evaluated the pharmacokinetics and pharmacodynamics of a novel 3-dose regimen of daclizumab in de novo hepatitis C liver transplant recipients. In 30 of 156 recipients receiving daclizumab, mycophenolate mofetil, tacrolimus, and no steroids (Arm 3 of Hep C 3 Liver Study), daclizumab (2, 2, and 1 mg/kg, respectively) was given on days 1, 3, and 8 posttransplant, respectively, with trough, peak (Cmax), and CD25 saturation (CDsat) measured sequentially. Mean daclizumab Cmax was 50.3 Ag/mL on day 1, and mean trough levels were 21.8, 25.7, and 9.9 μg/mL on days 3, 8, and 30, respectively. A significant decline in CDsat (mean, 15.7% to 4.7%) was observed on day 1 and was sustained throughout the study (2.8% on day 30). Daclizumab concentration ≥5 μg/mL was the level where most of the effect on CDsat was noticed. Elevated baseline CDsat, was observed in African Americans, patients weighing ≤75 kg, and patients <60 years of age. After 365 days, 2 patients had experienced 3 rejections, 10 patients had recurrent hepatitis C, 4 patients died, and 2 grafts were lost. In conclusion, this novel 3-dose regimen is effective in rapidly achieving high therapeutic concentration of daclizumab and a significant decline in CDsat lasting over 30 days.

UR - http://www.scopus.com/inward/record.url?scp=33645538211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645538211&partnerID=8YFLogxK

U2 - 10.1002/lt.20631

DO - 10.1002/lt.20631

M3 - Article

C2 - 16456831

AN - SCOPUS:33645538211

VL - 12

SP - 585

EP - 591

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 4

ER -